Evidence map›Paper›PMID 27680666›Full record

ArticleJournal of the American Heart Association2016

Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.

Rene Baudrand, Nidhi Gupta, Amanda E Garza, Anand Vaidya, Jane A Leopold, Paul N Hopkins, Xavier Jeunemaitre, Claudio Ferri, Jose R Romero, Jonathan Williams and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Frontiers in genetics · 2022
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone.Hypertension (Dallas, Tex. : 1979) · 2020 · on this map
    Observational
  18. Article
  19. Article
  20. MicroRNA-451a targets caveolin-1 in stomach cancer cells.International journal of clinical and experimental pathology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Rene BaudrandDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Department of Endocrinology, School of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile.
Nidhi GuptaDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Amanda E GarzaDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Anand VaidyaDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jane A LeopoldDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Paul N HopkinsCardiovascular Genetics, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Xavier JeunemaitreCentre d'Investigation Clinique Inserm/AP, Departement de Genetique, Hȏpital European Georges Pompidou, Paris, France.
Claudio FerriDepartment MeSVA, San Salvatore Hospital, University of L'Aquila, Italy.
Jose R RomeroDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jonathan WilliamsDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Joseph LoscalzoDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Gail K AdlerDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Gordon H WilliamsDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Luminita H PojogaDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA lpojoga@partners.org.
Harvard University · USBrigham and Women's Hospital · USHôpital Européen · FRPontificia Universidad Católica de Chile · CLSan Salvatore Hospital · ITUniversity of Utah · US

Funding

Interactions Between Adrenal and Parathyroid Hormones in Human HealthR01DK107407 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2015 to 2019
$2.5M
Caveolin-1 and vascular dysfunctionR01HL104032 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI POJOGA, LUMINITA · 2010 to 2014
$2.1M
Aldosteron, Intracellular Leukocyte Magnesium and Inflammation in DiabetesR01HL096518 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROMERO, JOSE R · 2009 to 2012
$1.9M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
Aldosterone, Autophagy, and Arterial StiffnessR01HL105301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A · 2010 to 2013
$1.6M
Aldosterone and Diabetic Cardiovascular Disease: Research and Mentoring ProgamK24HL103845 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 2011 to 2021
$1.6M
Vitamin D and Hormonal Mechanisms of Cardiovascular Disease in ObesityK23HL111771 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2012 to 2016
$805k
Doris Duke Charitable Foundation 2015085NHLBI NIH HHS K23 HL111771NHLBI NIH HHS K24 HL103845NHLBI NIH HHS L30 HL104553NHLBI NIH HHS R01 HL096518NHLBI NIH HHS R01 HL104032NHLBI NIH HHS R01 HL105301NHLBI NIH HHS U01 HL125215NIDDK NIH HHS R01 DK107407
6 · The paper itself

Abstract

backgroundOveractivation of the aldosterone and mineralocorticoid receptor (MR) pathway is associated with hyperglycemia and dyslipidemia. Caveolin 1 (cav-1) is involved in glucose/lipid homeostasis and may modulate MR signaling. We investigated the interplay between cav-1 and aldosterone signaling in modulating insulin resistance and dyslipidemia in cav-1-null mice and humans with a prevalent variant in the CAV1 gene. METHODS AND

resultsIn mouse studies, cav-1 knockout mice exhibited higher levels of homeostatic model assessment of insulin resistance, cholesterol, and resistin and lower ratios of high- to low-density lipoprotein (all P<0.001 versus wild type). Moreover, cav-1 knockout mice displayed hypertriglyceridemia and higher mRNA levels for resistin, retinol binding protein 4, NADPH oxidase 4, and aldose reductase in liver and/or fat tissues. MR blockade with eplerenone significantly decreased glycemia (P<0.01), total cholesterol (P<0.05), resistin (P<0.05), and described enzymes, with no effect on insulin or triglycerides. In the human study, we analyzed the CAV1 gene polymorphism rs926198 in 556 white participants; 58% were minor allele carriers and displayed higher odds of insulin resistance (odds ratio 2.26 [95% CI 1.40-3.64]) and low high-density lipoprotein (odds ratio 1.54 [95% CI 1.01-3.37]). Aldosterone levels correlated with higher homeostatic model assessment of insulin resistance and resistin and lower high-density lipoprotein only in minor allele carriers. CAV1 gene expression quantitative trait loci data revealed lower cav-1 expression in adipose tissues by the rs926198 minor allele.

conclusionsOur findings in mice and humans suggested that decreased cav-1 expression may activate the effect of aldosterone/MR signaling on several pathways of glycemia, dyslipidemia, and resistin. In contrast, hyperinsulinemia and hypertriglyceridemia are likely mediated by MR-independent mechanisms. Future human studies will elucidate the clinical relevance of MR blockade in patients with genotype-mediated cav-1 deficiency.

Indexed as

Adipose TissueAdolescentAdultAgedAldehyde ReductaseAldosteroneAnimalsBlood GlucoseCaveolin 1CholesterolDyslipidemiasEplerenoneFemaleGene FrequencyGlucoseHomeostasisAldehyde ReductaseAldosteroneBlood GlucoseCAV1 protein, humanCav1 protein, mouseCaveolin 1CholesterolEplerenoneGlucoseInsulinLipoproteins, HDLMineralocorticoid Receptor AntagonistsNADPH Oxidase 4Nox4 protein, mouseRbp4 protein, mouseReceptors, MineralocorticoidResistinRetinol-Binding Proteins, PlasmaRetn protein, mouseRNA, MessengerSpironolactoneTriglyceridesaldosteronecaveolin 1dyslipidemiaeplerenoneinsulin resistancemineralocorticoid receptor

Identifiers

PMID27680666
PMCPMC5121487
OpenAlexW2526367878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.